Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

被引：0
|
作者：
N. I. Bouwer
T. G. Steenbruggen
J. van Rosmalen
H. N. Rier
J. J. E. M. Kitzen
M. L. van Bekkum
A. J. Ten Tije
P. C. de Jong
J. C. Drooger
C. Holterhues
C. H. Smorenburg
M. J. M. Kofflard
E. Boersma
G. S. Sonke
M.-D. Levin
A. Jager
机构：
[1] Albert Schweitzer Hospital,Department of Internal Medicine
[2] Albert Schweitzer Hospital,Department of Cardiology
[3] The Netherlands Cancer Institute,Department of Medical Oncology
[4] Erasmus MC,Department of Biostatistics
[5] University Medical Centre Rotterdam,Department of Medical Oncology
[6] Erasmus MC,Department of Medical Oncology
[7] Cancer Institute,Department of Medical Oncology
[8] Reinier de Graaf Hospital,Department of Medical Oncology
[9] Amphia Hospital,Department of Medical Oncology
[10] Sint Antonius Hospital,Department of Medical Oncology
[11] Ikazia Hospital,Department of Cardiology
[12] Haga Hospital,undefined
[13] Erasmus MC,undefined
[14] University Medical Centre Rotterdam,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 186卷
关键词：
HER2-positive metastatic breast cancer; Trastuzumab treatment; Cardiotoxicity; LVEF monitoring; Screening for cardiotoxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：851 / 862
页数：11
相关论文
共 50 条
  • [41] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
    Sawaki, Masataka
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
  • [42] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study
    F Carabantes-Ocón
    E Saez-Lara
    L Burgos-Garcia
    E Villar-Chamorro
    A Casaus-Hazañas
    S Luna
    C Martínez
    Breast Cancer Research, 9
  • [43] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients:: a clinical study
    Carabantes-Ocon, F.
    Saez-Lara, E.
    Burgos-Garcia, L.
    Villar-Chamorro, E.
    Casaus-Hazanas, A.
    Luna, S.
    Martinez, C.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [44] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [45] Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
    Cortes, Javier
    Hurvitz, Sara A.
    Im, Seock-Ah
    Iwata, Hiroji
    Curigliano, Giuseppe
    Kim, Sung-Bae
    Chiu, Joanne W. Y.
    Pedrini, Jose L.
    Li, Wei
    Yonemori, Kan
    Bianchini, Giampaolo
    Loi, Sherene
    Borges, Giuliano S.
    Wang, Xian
    Bachelot, Thomas
    Nakatani, Shunsuke
    Ashfaque, Shahid
    Liang, Zhengkang
    Egorov, Anton
    Hamilton, Erika
    NATURE MEDICINE, 2024, 30 (08) : 2208 - 2215
  • [46] Pooled cardiac safety analysis of patients with HER2-positive metastatic breast cancer receiving trastuzumab.
    Muehlbauer, S.
    Revil, C.
    Leyland-Jones, B.
    Bell, R.
    Baselga, J.
    Marty, M.
    Jones, A.
    Feyereislova, A. F.
    CANCER RESEARCH, 2009, 69 (02) : 389S - 389S
  • [47] Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis
    Russillo, Michelangelo
    Ferretti, Gianluigi
    Vidiri, Antonello
    Gasparro, Simona
    Cognetti, Francesco
    Pellegrini, Domenica
    Fabi, Alessandra
    IN VIVO, 2018, 32 (04): : 839 - 842
  • [48] Long-term Outcome of HER2-positive Early Breast Cancer Patients in the Trastuzumab Era: a Single Centre Experience
    Aravind, P.
    Jingree, C.
    Castell, F.
    Rigg, A.
    CLINICAL ONCOLOGY, 2017, 29 (06) : E97 - E97
  • [49] Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
    Yardley, D. A.
    Tripathy, D.
    Brufsky, A. M.
    Rugo, H. S.
    Kaufman, P. A.
    Mayer, M.
    Magidson, J.
    Yoo, B.
    Quah, C.
    Yood, M. Ulcickas
    BRITISH JOURNAL OF CANCER, 2014, 110 (11) : 2756 - 2764
  • [50] Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy
    Alowais, Shuroug A.
    Luk, Samantha O.
    Kim, E. Bridget
    Alsuhebany, Nada
    Zangardi, Mark
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (06) : 992 - 998
12345